Clinical trials: Demyelinating Diseases
Multiple Sclerosis
Kesimpta Pregnancy and Infant Safety Study Using Real World Data
The study is an observational retrospective cohort study using longitudinal secondary data. Pregnant women with MS are assessed for exposure to Kesimpta and other MS disease modifying drugs (MSDMD) and followed up for adverse…
- Trial name
- NCT06156683
- Testing
- Multiple sclerosis disease modifying drug
- Where
- Switzerland
- Volunteers
- 1,500 people
- Sponsor
- Novartis Pharmaceuticals
Lysosomal Storage Disease, Metachromatic Leukodystrophy
Gene Therapy for Metachromatic Leukodystrophy (MLD)
This Phase I/II clinical trial consists of the application of lentiviral vector-based gene therapy to patients affected by Metachromatic Leukodystrophy (MLD), a rare inherited Lysosomal Storage Disorder (LSD) resulting from…
- Trial name
- NCT01560182
- Testing
- OTL-200 Gene Therapy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Orchard Therapeutics
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- SAkuraSun (NCT05199688)
- Testing
- Satralizumab
- Where
- 14 sites in United States, Argentina and 7 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Healthy, Multiple Sclerosis
Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers
The purpose of this study is to characterize the pharmacokinetic (PK) profile, safety, and tolerability of peginterferon beta-1a (BIIB017) delivered by the single-use autoinjector or prefilled syringe (PFS) in healthy volunteers…
- Trial name
- NCT01610310
- Testing
- BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS), BIIB017 (peginterferon beta-1a) Autoinjector
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT02753088
- Testing
- BCD-063, Copaxone-Teva
- Volunteers
- 158 people
- Sponsor
- Biocad
Multiple Sclerosis, Relapsing-Remitting
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
The Canadian Multiple Sclerosis Working Group (CMSWG) has developed practical recommendations on how neurologists can assess the status of subjects on disease modifying drugs (DMDs) and decide when it may be necessary to modify…
- Trial name
- CanTOR (NCT01142583)
- Volunteers
- 192 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
- Trial name
- NCT00097188
- Testing
- rituximab
- Where
- 31 sites in United States
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS)
PRISM Registry: Pseudobulbar Affect Registry Series
PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease
- Trial name
- NCT01366027
- Where
- United States
- Volunteers
- 5,290 people
- Sponsor
- Avanir Pharmaceuticals
Restless Legs Syndrome, Multiple Sclerosis
Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms
Study will look at a limited number of participants with various chronic symptoms. Investigating a new and novel form of hypnosis application called "Direct Autonomic Experience (DAX)" which is using combination of visualization…
- Conditions
- Restless Legs Syndrome, Multiple Sclerosis, Trauma, Psychological, Chronic Disease
- Trial name
- HDAX1 (NCT04303143)
- Testing
- Self-Hypnosis, Direct Autonomic Experience Control
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inner Group Inc.
Relapsing Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the efficacy and safety of peginterferon beta-1a produced by CinnaGen compared with CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT05242133
- Testing
- Pegylated interferon beta-1a, Interferon Beta-1A Prefilled Syringe
- Where
- Iran
- Volunteers
- 168 people
- Sponsor
- Cinnagen
Secondary Progressive Multiple Sclerosis
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS
- Trial name
- NCT01181089
- Testing
- Baminercept
- Sponsor
- Biogen
Neuromyelitis Optica
In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO
This is a fundamental, prospective, multi-centres, interventional non-comparative study without the administration of a study product to patients.
- Trial name
- NCT04629274
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- Imcyse SA
Multiple Sclerosis, Relapsing-Remitting
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device).
- Trial name
- NCT02652091
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
- Where
- 23 sites in United States
- Volunteers
- 146 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
The purpose of the study is 1) to study the safety and tolerability of escalating doses of myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of T Cell Vaccine ion the clinical course of MS.
- Trial name
- DES (NCT00587691)
- Testing
- Tovaxin Autologous T Cell Vaccine
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Opexa Therapeutics, Inc.
Stroke, Parkinson Disease
Videofluoroscopic Swallowing Study (VFSS)
The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.
- Conditions
- Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia
- Trial name
- PORSCHE (NCT03387267)
- Testing
- Dysphagia Detection System
- Where
- 13 sites in United States, Finland
- Volunteers
- 452 people
- Sponsor
- Société des Produits Nestlé (SPN)
Multiple Sclerosis
Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms
To evaluate the safety and tolerability of oral administration of PTL201 for relief of spasticity-related symptoms in 70 MS patients and to evaluate the efficacy of oral administration of PTL201 in relief of spasticity-related…
- Trial name
- NCT03005119
- Testing
- PTL201
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- PhytoTech Therapeutics, Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course.
- Trial name
- HELIPAD 1 (NCT03779828)
- Testing
- HOME LINK
- Where
- 10 sites in France
- Volunteers
- 11 people
- Sponsor
- CSL Behring
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments.
- Trial name
- NCT04956744
- Testing
- IMS001
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- ImStem Biotechnology
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes…
- Trial name
- NCT00649792
- Testing
- Fampridine-SR
- Where
- 42 sites in United States, Canada
- Volunteers
- 214 people
- Sponsor
- Acorda Therapeutics
Relapsing Forms of Multiple Sclerosis
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study.
- Trial name
- FUSION (NCT05798520)
- Testing
- BIIB091, DRF
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 127 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.